KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Net Cash Flow (2016 - 2025)

NovoCure's Net Cash Flow history spans 12 years, with the latest figure at -$241.2 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 949.62% year-over-year to -$241.2 million; the TTM value through Dec 2025 reached -$63.1 million, up 17.3%, while the annual FY2025 figure was -$63.1 million, 17.3% up from the prior year.
  • Net Cash Flow for Q4 2025 was -$241.2 million at NovoCure, down from $192.5 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $330.1 million in Q3 2021 and bottomed at -$481.0 million in Q4 2021.
  • The 5-year median for Net Cash Flow is $9.9 million (2023), against an average of -$7.1 million.
  • The largest annual shift saw Net Cash Flow crashed 4596.91% in 2021 before it skyrocketed 2435.48% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at -$481.0 million in 2021, then soared by 73.32% to -$128.4 million in 2022, then surged by 166.89% to $85.9 million in 2023, then crashed by 126.76% to -$23.0 million in 2024, then crashed by 949.62% to -$241.2 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Net Cash Flow are -$241.2 million (Q4 2025), $192.5 million (Q3 2025), and $22.4 million (Q2 2025).